Intracellular and extracellular TAU as drivers of lysosomal failure in human neuronal models of frontotemporal dementia
Active Grant Awarded
- Award ID
- K99NS150834
- Recipient
-
The Washington University UEI L6NFUM28LQM5
- Awarding agency
-
National Institute of Neurological Disorders and Stroke
National Institutes of Health, Department of Health and Human Services
- Obligated
- $113,919
Award facts
- Assistance listing
- 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders
- Completion date 10% complete
- Place of performance
- St. Louis, MO 63110, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services, through the National Institutes of Health's National Institute of Neurological Disorders and Stroke, awarded The Washington University (Office of Sponsored Research Services) a grant totaling $113,919 on September 9, 2026, under Assistance Listing 93.853, Extramural Research Programs in the Neurosciences and Neurological Disorders. The award runs through August 31, 2028, with place of performance in St. Louis, MO 63110.
The funded project is a K99-phase effort testing whether lysosomal failure occurs upstream of tau aggregation in frontotemporal lobar degeneration with tau inclusions (FTLD-tau). The project uses human induced pluripotent stem cell-derived neurons and super-resolution microscopy to examine how phosphorylated tau (PTAU-THR231) and the pathogenic MAPT mutation R406W affect lysosomal motility, autophagosome-lysosome fusion, and cargo degradation. The source reports prior findings that an analog of the FDA-approved drug glibenclamide rescues these defects. During the K99 phase, the principal investigator will gain training in electron microscopy (EM/cryo-EM) and advanced lysosomal imaging. The source does not name sub-recipients for this award.
Description
- Abstract
- /summary protein aggregation is a hallmark of neurodegenerative diseases, and mounting evidence implicates lysosomal failure as a key driver of proteostasis collapse. However, IT remains unknown when lysosomal dysfunction emerges relative to pathology and how IT can be effectively targeted. My long-term goal is to establish an independent research program that defines the molecular cascade leading to lysosomal collapse preceding TAU aggregation, to uncover therapeutic targets that can halt or reverse disease progression. In frontotemporal lobar degeneration with TAU inclusions (FTLD-TAU), the microtubule-associated protein TAU, encoded by mapt, becomes hyperphosphorylated and forms pathological aggregates. Mutations in mapt cause familial FTLD-TAU, but the mechanisms linking these mutations to lysosomal dysfunction and TAU aggregation remain unclear. Using human induced pluripotent stem cell (IPSC)-derived neurons and super- resolution microscopy, I discovered that phosphorylated TAU (PTAU-THR231) accumulates at the lysosomal membrane, impeding degradation, and that a pathogenic mapt mutation (R406W) disrupts lysosomal motility, autophagosome-lysosome fusion, and cargo degradation. These defects are rescued by an analog of the FDA- approved drug glibenclamide, revealing a promising therapeutic avenue. Yet, IT remains unknown whether distinct mapt mutations or TAU post-translational modifications differentially impair lysosomal trafficking and degradation, how these early disruptions initiate TAU aggregation, and how TAU aggregates, in turn, exacerbate lysosomal and autophagic failure. I hypothesize that lysosomal failure occurs upstream of TAU aggregation and is mediated by specific phospho- epitopes of TAU. During the K99 phase, I will gain training in electron microscopy (EM/CRYO-EM) and advanced lysosomal imaging to visualize TAU within lysosomal compartments. In the R00 phase, I will integrate these approaches with my expertise in TAU biology, stem cell modeling, and autophagy to define how TAU aggregates drive lysosomal vulnerability and to test pharmacological rescue strategies. Through this integrated research and mentored training plan, I will uncover fundamental mechanisms of lysosomal impairment in human neurons, establish new experimental platforms for TAU-lysosome biology, and lay the foundation for an independent research program targeting lysosomal pathways in neurodegeneration.
Quick answers
Who received award K99NS150834?
K99NS150834 was awarded to The Washington University by National Institute of Neurological Disorders and Stroke (National Institutes of Health) on September 9, 2026.
How much is award K99NS150834 worth?
$113,919 has been obligated on K99NS150834.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award